Literature DB >> 1165476

Passive transfer of experimental autoimmune myasthenia by lymph node cells in inbred guinea pigs.

R Tarrab-Hazdi, A Aharonov, O Abramsky, I Yaar, S Fuchs.   

Abstract

Passive transfer of experimental autoimmune myasthenia (EAM) was performed with lymph node cells from donor guinea pigs immunized with purified acetylcholine receptor (AChR) from Torpedo californica. Recipient animals revealed the same clinical signs and electromyographic patterns as observed in actively challenged animals. These phenomena are parallel to the clinical manifestations of the human disease myasthenia gravis, in which cellular response to AChR was recently demonstrated.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1165476      PMCID: PMC2189911          DOI: 10.1084/jem.142.3.785

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  6 in total

1.  Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis.

Authors:  O Abramsky; A Aharonov; C Webb; S Fuchs
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

2.  Cell-mediated immunity to myelin basic protein in acute disseminated encephalomyelitis.

Authors:  R P Lisak; P O Behan; B Zweiman; T Shetty
Journal:  Neurology       Date:  1974-06       Impact factor: 9.910

3.  Autoimmune response to acetylcholine receptor.

Authors:  J Patrick; J Lindstrom
Journal:  Science       Date:  1973-05-25       Impact factor: 47.728

Review 4.  Experimental allergic encephalomyelitis and autoimmune disease.

Authors:  P Y Paterson
Journal:  Adv Immunol       Date:  1966       Impact factor: 3.543

5.  Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis.

Authors:  A Aharonov; R Tarrab-Hazdai; O Abramsky; S Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

6.  Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs.

Authors:  V A Lennon; J M Lindstrom; M E Seybold
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

  6 in total
  15 in total

Review 1.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

Review 2.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 3.  Progress in myasthenia gravis.

Authors:  C W Havard
Journal:  Br Med J       Date:  1977-10-15

Review 4.  Immunopathology of acetylcholine receptors in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Springer Semin Immunopathol       Date:  1982

5.  Experimental autoimmune myasthenia gravis.

Authors:  J Lindstrom
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

6.  High numbers of autoantigen-reactive mononuclear cells expressing interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) are present in cord blood.

Authors:  M Yu; S Fredrikson; J Link; H Link
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

7.  The relation of clinical disease to antibody titre, proliferative response and neurophysiology in murine experimental autoimmune myasthenia gravis.

Authors:  A R Pachner; F S Kantor
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

8.  Carbamylcholine modulation of E-rosette formation. Effect of plasmapheresis in myasthenia gravis.

Authors:  Y Mizuno; J Humphrey; H M Dosch; E W Gelfand
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

9.  Acetylcholine receptor-specific suppressive T-cell factor from a retrovirally transformed T-cell line.

Authors:  F Sinigaglia; C Gotti; R Castagnoli; F Clementi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

10.  Myasthenia gravis treatment: twelve years experience on 110 patients.

Authors:  G Valli; S Jann; S Premoselli; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1987-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.